Free Trial

Pharvaris (PHVS) Expected to Announce Quarterly Earnings on Wednesday

Pharvaris logo with Medical background

Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.

Pharvaris Trading Down 2.3 %

Pharvaris stock traded down $0.34 during midday trading on Friday, hitting $14.28. The stock had a trading volume of 19,107 shares, compared to its average volume of 72,079. Pharvaris has a 52-week low of $13.48 and a 52-week high of $25.50. The company has a market capitalization of $746.70 million, a PE ratio of -5.10 and a beta of -2.84. The firm's fifty day moving average is $16.31 and its two-hundred day moving average is $18.70.

Wall Street Analyst Weigh In

Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.

Get Our Latest Analysis on Pharvaris

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

Featured Stories

Earnings History for Pharvaris (NASDAQ:PHVS)

Should You Invest $1,000 in Pharvaris Right Now?

Before you consider Pharvaris, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.

While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Make Your Money Work Harder: The Power of Dividend Investing
7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines